Why MUC16 mutations lead to a better prognosis: A study based on The Cancer Genome Atlas gastric cancer cohort
Authors:
Open Access
- 16 June 2021
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 9 (17) , 4143-4158
Abstract
MUC16, encoding cancer antigen 125, is a frequently mutated gene in gastric cancer. In addition, MUC16 mutations seem to result in a better prognosis in gastric cancer. However, the mechanisms that lead to a better prognosis by MUC16 mutations have not yet been clarified. To delve deeper into the underlying mechanisms that explain why MUC16 mutations signal a better prognosis in gastric cancer. We used multi-omics data, including mRNA, simple nucleotide variation, copy number variation and methylation data from The Cancer Genome Atlas, to explore the relationship between MUC16 mutations and prognosis. Cox regression and random survival forest algorithms were applied to search for hub genes. Gene set enrichment analysis was used to elucidate the molecular mechanisms. Single-sample gene set enrichment analysis and “EpiDISH” were used to assess immune cells infiltration, and “ESTIMATE” for analysis of the tumor microenvironment. Our study found that compared to the wild-type group, the mutation group had a better prognosis. Additional analysis indicated that the MUC16 mutations appear to activate the DNA repair and p53 pathways to act as an anti-tumor agent. We also identified a key gene, NPY1R (neuropeptide Y receptor Y1), which was significantly more highly expressed in the MUC16 mutations group than in the MUC16 wild-type group. The high expression of NPY1R predicted a poorer prognosis, which was also confirmed in a separate Gene Expression Omnibus cohort. Further susceptibility analysis revealed that NPY1R might be a potential drug target for gastric cancer. Furthermore, in the analysis of the tumor microenvironment, we found that immune cells in the mutation group exhibited higher anti-tumor effects. In addition, the tumor mutation burden and cancer stem cells index were also higher in the mutation group than in the wild-type group. We speculated that the MUC16 mutations might activate the p53 pathway and DNA repair pathway: alternatively, the tumor microenvironment may be involved.Keywords
This publication has 39 references indexed in Scilit:
- To Develop and Validate the Combination of RNA Methylation Regulators for the Prognosis of Patients with Gastric CancerOncoTargets and Therapy, 2020
- Prognostic Prediction Using a Stemness Index-Related Signature in a Cohort of Gastric CancerFrontiers in Molecular Biosciences, 2020
- Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric CancerJAMA Oncology, 2018
- Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seqNature Communications, 2018
- Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell SequencingCell, 2018
- Mining TCGA database for genes of prognostic value in glioblastoma microenvironmentAging, 2018
- Machine Learning Identifies Stemness Features Associated with Oncogenic DedifferentiationCell, 2018
- Gastric cancerThe Lancet, 2016
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- Inferring tumour purity and stromal and immune cell admixture from expression dataNature Communications, 2013